Legend Biotech (NASDAQ:LEGN) Hits New 12-Month Low Following Analyst Downgrade

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report)’s share price reached a new 52-week low on Monday after Evercore downgraded the stock from an outperform rating to an in-line rating. Evercore now has a $20.00 price target on the stock. Legend Biotech traded as low as $16.09 and last traded at $15.9850, with a volume of 2,082,893 shares changing hands. The stock had previously closed at $17.50.

Several other brokerages have also commented on LEGN. Morgan Stanley dropped their price target on Legend Biotech from $49.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, November 11th. Weiss Ratings upgraded shares of Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Benchmark reaffirmed a “buy” rating on shares of Legend Biotech in a research report on Tuesday, July 28th. JPMorgan Chase & Co. dropped their price target on shares of Legend Biotech from $35.00 to $33.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Legend Biotech in a research note on Friday, October 30th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Legend Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $48.64.

Read Our Latest Stock Analysis on LEGN

Insider Buying and Selling

In other Legend Biotech news, CFO Carlos Santos sold 5,430 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the sale, the chief financial officer owned 14,246 shares of the company’s stock, valued at approximately $130,208.44. This represents a 27.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total transaction of $258,920.20. Following the completion of the sale, the director owned 52,731 shares in the company, valued at approximately $498,835.26. This trade represents a 34.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.02% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors have recently modified their holdings of LEGN. Parallel Advisors LLC lifted its holdings in Legend Biotech by 173.9% in the first quarter. Parallel Advisors LLC now owns 2,084 shares of the company’s stock valued at $38,000 after buying an additional 1,323 shares during the period. Toth Financial Advisory Corp purchased a new position in shares of Legend Biotech during the 3rd quarter valued at $50,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Legend Biotech in the second quarter worth $92,000. Nykredit A S bought a new stake in Legend Biotech during the second quarter valued at $162,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Legend Biotech during the third quarter valued at $136,000. Institutional investors and hedge funds own 70.89% of the company’s stock.

Legend Biotech Price Performance

The stock has a 50-day moving average price of $19.37 and a two-hundred day moving average price of $22.10.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $359.50 million during the quarter, compared to analyst estimates of $361.46 million. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The firm’s revenue was up 32.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) earnings per share. On average, equities research analysts anticipate that Legend Biotech Corporation Sponsored ADR will post -0.02 earnings per share for the current year.

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

Further Reading

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.